|
1
|
Raunio H and Rahnasto-Rilla M: CYP2A6:
Genetics, structure, regulation, and function. Drug Metabol Drug
Interact. 27:73–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Raunio H, Rautio A and Pelkonen O: The
CYP2A subfamily: Function, expression and genetic polymorphism.
IARC Sci Publ. 148:197–207. 1999.
|
|
3
|
Pelkonen P, Lang MA, Wild CP, Negishi M
and Juvonen RO: Activation of aflatoxin B1 by mouse CYP2A enzymes
and cytotoxicity in recombinant yeast cells. Eur J Pharmacol.
292:67–73. 1994.PubMed/NCBI
|
|
4
|
Camus AM, Geneste O, Honkakoski P,
Béréziat JC, Henderson CJ, Wolf CR, Bartsch H and Lang MA: High
variability of nitrosamine metabolism among individuals: Role of
cytochromes P450 2A6 and 2E1 in the dealkylation of
N-nitrosodimethylamine and N-nitrosodiethylamine in mice and
humans. Mol Carcinog. 7:268–275. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oscarson M: Genetic polymorphisms in the
cytochrome P450 2A6 (CYP2A6) gene: Implications for interindividual
differences in nicotine metabolism. Drug Metab Dispos. 29:91–95.
2001.PubMed/NCBI
|
|
6
|
Tyndale RF and Sellers EM: Variable
CYP2A6-mediated nicotine metabolism alters smoking behavior and
risk. Drug Metab Dispos. 29:548–552. 2001.PubMed/NCBI
|
|
7
|
Miyamoto M, Umetsu Y, Dosaka-Akita H,
Sawamura Y, Yokota J, Kunitoh H, Nemoto N, Sato K, Ariyoshi N and
Kamataki T: CYP2A6 gene deletion reduces susceptibility to lung
cancer. Biochem Biophys Res Commun. 261:658–660. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sowbhagya HB: Chemistry, technology, and
nutraceutical functions of celery (Apium graveolens L.): An
overview. Crit Rev Food Sci Nutr. 54:389–398. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Madkour NK: Beneficial role of celery oil
in lowering the di(2-ethylhexyl) phthalate-induced testicular
damage. Toxicol Ind Health. 30:861–872. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jakovljevic V, Raskovic A, Popovic M and
Sabo J: The effect of celery and parsley juices on pharmacodynamic
activity of drugs involving cytochrome P450 in their metabolism.
Eur J Drug Metab Pharmacokinet. 27:153–156. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. Biol
Chem. 193:265–274. 1951.
|
|
12
|
Pinto LF, Moraes E, Albano RM, Silva MC,
Godoy W, Glisovic T and Lang MA: Rat oesophageal cytochrome P450
(CYP) monooxygenase system: Comparison to the liver and relevance
in N-nitrosodiethylamine carcinogenesis. Carcinogenesis.
22:1877–1883. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
14
|
Aitio A: A simple and sensitive assay of
7-ethoxycoumarin deethylation. Anal Biochem. 85:488–491. 1978.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Farooq S, Shakeel-u-Rehman, Dangroo NA,
Priya D, Banday JA, Sangwan PL, Qurishi MA, Koul S and Saxena AK:
Isolation, cytotoxicity evaluation and HPLC-quantification of the
chemical constituents from Prangos pabularia. PLoS One.
9:e1087132014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Perloff ES, Mason AK, Dehal SS, Blanchard
AP, Morgan L, Ho T, Dandeneau A, Crocker RM, Chandler CM, Boily N,
et al: Validation of cytochrome P450 time-dependent inhibition
assays: A two-time point IC50 shift approach facilitates kinact
assay design. Xenobiotica. 39:99–112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee JY, Lee SY, Oh SJ, Lee KH, Jung YS and
Kim SK: Assessment of drug-drug interactions caused by
metabolism-dependent cytochrome P450 inhibition. Chem Biol
Interact. 198:49–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mäenpää J, Sigusch H, Raunio H, Syngelmä
T, Vuorela P, Vuorela H and Pelkonen O: Differential inhibition of
coumarin 7-hydroxylase activity in mouse and human liver
microsomes. Biochem Pharmacol. 45:1035–1042. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Juvonen RO, Gynther J, Pasanen M, Alhava E
and Poso A: Pronounced differences in inhibition potency of lactone
and non-lactone compounds for mouse and human coumarin
7-hydroxylases (CYP2A5 and CYP2A6). Xenobiotica. 30:81–92. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wood AW: Genetic regulation of coumarin
hydroxylase activity in mice. Biochemical characterization of the
enzyme from two inbred strains and their F1 hybrid. J Biol Chem.
254:5641–5646. 1979.PubMed/NCBI
|
|
21
|
Rahnasto M, Raunio H, Poso A and Juvonen
RO: More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme
activities by derivatives of phenylethylamine and benzaldehyde.
Xenobiotica. 33:529–539. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lindberg RL and Negishi M: Alteration of
mouse cytochrome P450coh substrate specificity by mutation of a
single amino-acid residue. Nature. 339:632–634. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Negishi M, Iwasaki M, Juvonen RO and Aida
K: Alteration of the substrate specificity of mouse 2A P450s by the
identity of residue-209: Steroid-binding site and orientation. J
Steroid Biochem Mol Biol. 43:1031–1036. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Visoni S, Meireles N, Monteiro L, Rossini
A and Pinto LF: Different modes of inhibition of mouse Cyp2a5 and
rat CYP2A3 by the food-derived 8-methoxypsoralen. Food Chem
Toxicol. 46:1190–1195. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Draper AJ, Madan A and Parkinson A:
Inhibition of coumarin 7-hydroxylase activity in human liver
microsomes. Arch Biochem Biophys. 341:47–61. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
von Weymarn LB, Zhang QY, Ding X and
Hollenberg PF: Effects of 8-methoxypsoralen on cytochrome P450
2A13. Carcinogenesis. 26:621–629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu YL, Xu Y, Li F, Chen H and Guo SL:
CYP2A6 deletion polymorphism is associated with decreased
susceptibility of lung cancer in Asian smokers: A meta-analysis.
Tumour Biol. 34:2651–2657. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mwenifumbo JC and Tyndale RF: Genetic
variability in CYP2A6 and the pharmacokinetics of nicotine.
Pharmacogenomics. 8:1385–1402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakajima M: Smoking behavior and related
cancers: The role of CYP2A6 polymorphisms. Curr Opin Mol Ther.
9:538–544. 2007.PubMed/NCBI
|
